{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Number of participants with a maximum grade of 3 or higher during the treatment period.","groups":[{"description":"Arm 1: Methotrexate 30 mg/m2 IM weekly","id":"OG000","title":"Arm 1: Methotrexate 30 mg/m2 IM Weekly"},{"description":"Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks","id":"OG001","title":"Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.","title":"Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0","type":"PRIMARY","unitOfMeasure":"Participants"}